BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37510722)

  • 1. Selected Parameters of Bone Turnover in Neuroendocrine Tumors-A Potential Clinical Use?
    Strzelczyk J; Wójcik-Giertuga M; Strzelczyk JK; Seńkowska AP; Biernacki K; Kos-Kudła B
    J Clin Med; 2023 Jul; 12(14):. PubMed ID: 37510722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoprotegerin and its correlations with new markers of bone formation and bone resorption in kidney transplant recipients.
    Malyszko J; Malyszko JS; Wolczynski S; Mysliwiec M
    Transplant Proc; 2003 Sep; 35(6):2227-9. PubMed ID: 14529897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship among circulating insulin-like growth factor components, biochemical markers of bone turnover and bone mineral density in postmenopausal women under the age of 60.
    Kim JG; Shin CS; Choi YM; Moon SY; Kim SY; Lee JY
    Clin Endocrinol (Oxf); 1999 Sep; 51(3):301-7. PubMed ID: 10469009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationships between age-related biochemical markers of bone turnover and OPG, TGF-β1 and TGF-β2 in native Chinese women.
    Chen C; Liang MK; Zhang H; Peng YQ; Wu XP; Wu XY; Liao EY
    Endocr Res; 2014; 39(3):105-14. PubMed ID: 24152296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
    Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status.
    Fahrleitner-Pammer A; Dobnig H; Piswanger-Soelkner C; Bonelli C; Dimai HP; Leb G; Obermayer-Pietsch B
    Wien Klin Wochenschr; 2003 May; 115(9):291-7. PubMed ID: 12793029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease.
    Doumouchtsis K; Perrea D; Doumouchtsis S; Tziamalis M; Poulakou M; Vlachos I; Kostakis A
    Ther Apher Dial; 2009 Feb; 13(1):49-55. PubMed ID: 19379170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levels of the bone turnover markers dickkopf-1, sclerostin, osteoprotegerin, osteopontin, osteocalcin and 25-hydroxyvitamin D in Swedish geriatric patients aged 75 years or older with a fresh hip fracture and in healthy controls.
    Wanby P; Nobin R; Von SP; Brudin L; Carlsson M
    J Endocrinol Invest; 2016 Aug; 39(8):855-63. PubMed ID: 26850415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. sRANKL/osteoprotegerin complex and biochemical markers in a cohort of male and female hemodialysis patients.
    Doumouchtsis KK; Kostakis AI; Doumouchtsis SK; Tziamalis MP; Tsigris C; Kostaki MA; Perrea DN
    J Endocrinol Invest; 2007 Oct; 30(9):762-6. PubMed ID: 17993768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women.
    Rogers A; Saleh G; Hannon RA; Greenfield D; Eastell R
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4470-5. PubMed ID: 12364420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis.
    Reyes-García R; Muñoz-Torres M; García DF; Mezquita-Raya P; García Salcedo JA; de Dios Luna J
    Menopause; 2010; 17(1):140-4. PubMed ID: 19574937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nuclear factor-kappa B ligand and osteoprotegerin levels in serum and gingival crevicular fluid in patients with bone metastases treated with zoledronic acid.
    Inanc M; Kaynar L; Enhos S; Pala C; Karaca H; Berk V; Ozkan M; Sıvgın S; Eser B; Cetin M; Elmali F
    Med Oncol; 2014 Mar; 31(3):837. PubMed ID: 24448976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cystatin C as a potential predictor of osteoprotegerin levels in healthy men, a cross-sectional, observational study.
    Kulcsar-Jakab E; Petho Z; Pap Z; Kalina E; Foldesi R; Balogh A; Antal-Szalmas P; Bhattoa HP
    BMC Musculoskelet Disord; 2015 Aug; 16():227. PubMed ID: 26311162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone Turnover Markers and Osteoprotegerin in Uncomplicated Pregnancy.
    Styczynska H; Lis K; Sobanska I; Pater A; Pollak J; Mankowska A
    EJIFCC; 2009 Jan; 19(4):193-202. PubMed ID: 27683317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chromogranin A, Ki-67 index and IGF-related genes in patients with neuroendocrine tumors.
    van Adrichem RC; Hofland LJ; Feelders RA; De Martino MC; van Koetsveld PM; van Eijck CH; de Krijger RR; Sprij-Mooij DM; Janssen JA; de Herder WW
    Endocr Connect; 2013; 2(4):172-7. PubMed ID: 24042314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating osteoprotegerin and leptin levels in postmenopausal women with and without osteoporosis.
    Grigorie D; Neacşu E; Marinescu M; Popa O
    Rom J Intern Med; 2003; 41(4):409-15. PubMed ID: 15526523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circadian concentrations of free testosterone, selected markers of bone metabolism, osteoprotegerin and its ligand sRANKL in obese postmenopausal women.
    Ostrowska Z; Kos-Kudła B; Marek B; Kajdaniuk D; Wołkowska-Pokrywa K
    Postepy Hig Med Dosw (Online); 2011 Oct; 65():658-67. PubMed ID: 22100799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological Features of Neuroendocrine Tumors in Gastroenteropancreatic Tract: A Single Center Study.
    Rafique Z; Qasim A; Zafar A; Ali S; Chughtai AS; Atiq A
    Cureus; 2022 Jul; 14(7):e27384. PubMed ID: 36046310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in the serum growth factors and osteoprotegerin after bone marrow transplantation: impact on bone and mineral metabolism.
    Baek KH; Lee WY; Oh KW; Kim HS; Han JH; Kang MI; Cha BY; Lee KW; Son HY; Kang SK; Kim CC
    J Clin Endocrinol Metab; 2004 Mar; 89(3):1246-54. PubMed ID: 15001618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of the Ki-67 proliferation marker as a prognostic factor in gastroenteropancreatic neuroendocrine tumours.
    Foltyn W; Zajęcki W; Marek B; Kajdaniuk D; Siemińska L; Zemczak A; Kos-Kudła B
    Endokrynol Pol; 2012; 63(5):362-6. PubMed ID: 23115069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.